<DOC>
	<DOCNO>NCT02429934</DOCNO>
	<brief_summary>This research trial patient diagnose systemic lupus erythematosus ( SLE ) swollen , tender joint ( call inflammatory polyarthritis ) SLE . The purpose clinical research study evaluate safety effectiveness treatment abatacept ( Abatacept ) 125mg inject subcutaneously ( skin ) weekly 16 week versus placebo injection ( substance active ingredient therefore may treatment benefit ) subject SLE inflammatory polyarthritis . The effectiveness assess primarily number swell , tender joint ( call joint count ) study visit . Study Medication Abatacept approve U.S. treat rheumatoid arthritis prescription approve U.S. Food Drug Administration treat SLE yet . In study , subject receive treatment either abatacept placebo week 16 week ( total 16 injection ) .</brief_summary>
	<brief_title>Abatacept SLE Arthritis ( IM101-330 )</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Lupus Erythematosus , Systemic</mesh_term>
	<mesh_term>Abatacept</mesh_term>
	<criteria>1 . Meet least 4 11 American College Rheumatology ( ACR ) 1997 criterion classification SLE ( see Appendix 1 ) .OR meet recent classification recommend SLICC ( Appendix 2 ) 6 2 . ≥3 swollen tender joint 2 examination least 2 week apart 8 week apart . 3 . SLEDAI2K score ≥4 indicate active disease . 4 . Documented positive ANA ( ≥1:80 ) and/or antidsDNA course SLE . 5 . Men woman , least 18 year age . Women childbearing potential must use adequate method ( ) contraception avoid pregnancy throughout study 2 month last study drug dose . They must negative serum urine pregnancy test prior start study medication . 6 . Background therapy allow : antimalarial ( dose constant ≥ one month study entry 16 week trial ) , methotrexate ( criteria antimalarial ) , azathioprine ( criterion ) , mycophenolate ( criterion ) , leflunomide ( criterion ) . During screen period 6 week randomization , daily prednisone ( equivalent ) regimen 20 mg daily may initiate treat moderate severe disease activity present screening . The initial steroid regimen require investigator patient believe risk would outweigh potential benefit . Patients take glucocorticoid study include treatment group analysis . *Steroids taper target dose 10 mg/day prednisone ( equivalent ) end Week 8 ( Day 56 ) . The steroid regimen taper quickly safely possible . Prednisone dose requirement higher 10 mg daily 8 week visit cause patient rule nonresponder abatacept treatment arm . 1 . Subjects active infection require oral IV antibiotic within one month first dose study medication . 2 . Subjects BILAG A system outside musculoskeletal system . 3 . Subjects positive quantiferon Gold test absence treatment tuberculosis . 4 . Subjects positive test active infection hepatitis B C past 6 month . Any confirm positive test HIV time prior entry study . 5 . Subjects active glomerulonephritis ( &gt; 3 g protein/24h and/or active urine sediment ) . 6 . Subjects active CNS disease . 7 . Subjects serious disease would require immunosuppressive parenteral antimicrobial therapy outside study protocol . 8 . Inability selfadminister subcutaneous injection , comply instruction , keep appointment study visit . 9 . Treatment rituximab within past 6 month ( B cell must detectable peripheral blood onset treatment study biologic ) , belimumab within past 5 month , cyclophosphamide within past 3 month . 10 . Treatment immunomodulatory biologic cyclophosphamide treatment abatacept allow . 11 . Patients require &gt; 20 mg prednisone daily . 12 . Women pregnant breast feeding . 13 . Women child bear potential unwilling unable use acceptable method avoid pregnancy entire study period 2 month last study drug . 14 . Subjects history cancer within last five year ( nonmelanoma skin cell cancer cure local resection ) . 15 . Any laboratory test result , opinion Investigator , might place subject unacceptable risk participation study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2016</verification_date>
	<keyword>Systemic Lupus Erythematosus ( SLE )</keyword>
	<keyword>Abatacept ( Orencia )</keyword>
	<keyword>Arthritis</keyword>
</DOC>